Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 2,911 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: ADHD
Interventions: OROS methylphenidate, No intervention; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 12 Years to 18 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Hypertension
Interventions: BMS-823778, Placebo matching with BMS-823778; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 22
States / cities: Jonesboro, Arkansas • Los Angeles, California • Palm Springs, California + 18 more

Conditions: Primary Myelofibrosis, MPN-associated Myelofibrosis
Interventions: Pomalidomide 0.5 mg, Placebo, Pomalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 17
States / cities: Scottsdale, Arizona • Los Angeles, California • Gainesville, Florida + 12 more

Conditions: Healthy Volunteers
Interventions: TAK-279, TAK-279 Placebo, Moxifloxacin, Moxifloxacin Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Alcohol Use Disorder
Interventions: Placebo, Spironolactone; Other · Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 21 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypertension
Interventions: Aliskiren, Ramipril, Hydrochlorothiazide, Amlodipine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 65 Years and older
Enrollment: 901 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: omega-3 fatty acid supplement, Placebo, Clinical assessments, Assessment of therapy complications, Magnetic Resonance Imaging, Correlative/special studies; Dietary Supplement · Other · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: HIV Infections, Peripheral Neuropathy
Interventions: Duloxetine, Duloxetine placebo, Methadone, Methadone placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: San Diego, California • Torrance, California • Aurora, Colorado + 5 more

Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Iron Deficiency, Iron-deficiency Anemia (IDA)
Interventions: Ferric Carboxymaltose, Ferrous Sulfate; Drug
Lead sponsor: Syed Hamza Mufarrih; Other
Eligibility: 18 Years to 100 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Bowling Green, Kentucky

Conditions: Hypertriglyceridemia
Interventions: CaPre, Placebo; Drug
Lead sponsor: Grace Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 53
States / cities: Birmingham, Alabama • Childersburg, Alabama • Encino, California + 44 more

Conditions: Obesity, Metabolic Disease
Interventions: Xla1, Placebo; Drug
Lead sponsor: YSOPIA Bioscience; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Gut Health, Gastrointestinal Symptoms, Safety in Healthy Adults
Interventions: IgG Binding Protein LT, Placebo; Dietary Supplement
Lead sponsor: Bactolife A/S; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Major Depressive Disorder
Interventions: Placebo, Escitalopram, JNJ-18038683; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 26
States / cities: Little Rock, Arkansas • Beverly Hills, California • Glendale, California + 23 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Ozanimod, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 6
States / cities: Berkeley, California • Fresno, California • Sacramento, California + 3 more

Conditions: Healthy Adults
Interventions: EC5026 oral capsule, Placebo oral capsule; Drug · Other
Lead sponsor: EicOsis Human Health Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Clostridium Difficile Infection, C.Difficile Diarrhea, CDI
Interventions: Low Dose FMT Capsule DE, Single Dose FMT Capsule DE, Placebo oral capsule; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: B-cell Chronic Lymphocytic Leukemia
Interventions: Lenalidomide, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 56
States / cities: Phoenix, Arizona • Fountain Valley, California • San Diego, California + 48 more

Conditions: Irritability Associated With Autism Spectrum Disorder
Interventions: Pimavanserin, Placebo; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 18
States / cities: Phoenix, Arizona • Glendale, California • San Rafael, California + 15 more

Conditions: Pharmacokinetics, Healthy Volunteers
Interventions: BTA-C585 oral capsules, BTA-C585 matching placebo; Drug
Lead sponsor: Biota Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Social Anxiety Disorder
Interventions: Cannabidiol, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Sickle Cell Disease, Sickle Cell Anemia
Interventions: Low Dose ICA-17043, High dose ICA-17043, Placebo; Drug
Lead sponsor: Icagen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 19
States / cities: Birmingham, Alabama • Oakland, California • San Francisco, California + 16 more

Conditions: Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases
Interventions: NHS7108, Zenpep®; Drug
Lead sponsor: Aimmune Nestlé Health Science US R&D, LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 14
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more

Conditions: Diabetic Nephropathy
Interventions: CTP-499; Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Acute Pain, Bunionectomy, Toe Fusion
Interventions: Carbidopa-Levodopa (100mg/25mg):, Naproxen; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 75 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Proton Magnetic Spectroscopy in Children and Adolescents With ADHD Before and After Treatment With OROS Methylphenidate

Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients

Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence

A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements

Spironolactone in Alcohol Use Disorder (SAUD)

A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly

Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

Combination Pain Therapy in HIV Neuropathy

IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches

A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)

Xla1 Christensenella Minuta, Phase I, Randomized, Partially Placebo-controlled Double-blind Protocol, Evaluating Safety, Tolerability and Impact on the Gut Microbiota in Healthy Volunteers, Overweight and Obese Adults

IgG Binding Protein LT in Support of a Healthy Gut on the Go

A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects

The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy

Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder

Safety and Pharmacokinetics Study of Multiple Ascending Doses of BTA-C585 in Healthy Volunteers

Cannabidiol as a Treatment for Social Anxiety Disorder (R61)

A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.

A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.

Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499

Novel Non-opioid Post-surgical Pain Treatment in Females